Angiopoietin1 contributes to the maintenance of cell quiescence in EVI1 high leukemia cells

Biochemical and Biophysical Research Communications

Volumn 416, Issue 3-4, 2011, Pages 239-245

  Ichihara, Emi ^a   Kaneda, Kazuko ^a   Saito, Yusuke ^a   Yamakawa, Norio ^a   Morishita, Kazuhiro ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

Author keywords

AML; Ang1; Cell cycle; EVI1; P18

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN RECEPTOR; ECOTROPIC VIRUS INTEGRATION SITE 1; PROTEIN P18; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CONTROLLED STUDY; DOWN REGULATION; ECOTROPIC VIRUS; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION;

ANGIOPOIETIN-1; ANIMALS; CELL CYCLE; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P18; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION REGULATION, LEUKEMIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; PROTO-ONCOGENES; TRANSCRIPTION FACTORS;

MUS;

EID: 84855874329     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.10.061     Document Type: Article

References (32)

1. Morishita K., Parker D.S., Mucenski M.L., et al. Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell lines. Cell 1988, 54:831-840.
2. Mucenski M.L., Taylor B.A., Ihle J.N., et al. Identification of a common ecotropic viral integration site, EVI-1, in the DNA of AKXD murine myeloid tumors. Mol. Cell. Biol. 1988, 8:301-308.
3. Morishita K., Parganas E., William C.L., et al. Activation of EVI1 gene expression in human acute myelogenous leukemias by translocations spanning 300-400 kilobases on chromosome band 3q26. Proc. Natl Acad. Sci. USA 1992, 89:3937-3941.
4. Mitani K., Ogawa S., Tanaka T., et al. Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia. EMBO J. 1994, 13:504-510.
5. Lugthart S., van Drunen E., van Norden Y., et al. High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Blood 2008, 111:4329-4337.
6. Valk P.J., Verhaak R.G., Beijen M.A., et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N. Engl. J. Med. 2004, 350:1617-1628.
7. Barjesteh van Waalwijk van Doorn-Khosrovani S., Erpelinck C., van Putten W.L., et al. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood 2003, 101:837-845.
8. Phillips R.L., Ernst R.E., Brunk B., et al. The genetic program of hematopoietic stem cells. Science 2000, 288:1635-1640.
9. Park I.K., He Y., Lin F., et al. Differential gene expression profiling of adult murine hematopoietic stem cells. Blood 2002, 99:488-498.
10. Shimizu S., Nagasawa T., Katoh O., et al. EVI1 is expressed in megakaryocyte cell lineage and enforced expression of EVI1 in UT-7/GM cells induces megakaryocyte differentiation. Biochem. Biophys. Res. Commun. 2002, 292:609-616.
11. Yuasa H., Oike Y., Iwama A., et al. Oncogenic transcription factor evi1 regulates hematopoietic stem cell proliferation through GATA-2 expression. EMBO J. 2005, 24:1976-1987.
12. Goyama S., Yamamoto G., Shimabe M., et al. EVI-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells. Cell Stem Cell 2008, 3:207-220.
13. Davis S., Aldrich T.H., Jones P.F., et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996, 87:1161-1169.
14. Suri C., Jones P.F., Patan S., et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996, 87:1171-1180.
15. Maisonpierre P.C., Suri C., Jones P.F., et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997, 277:55-60.
16. Valenzuela D.M., Griffiths J.A., Rojas J., et al. Angiopoietins 3 and 4: diverging gene counterparts in mice and humans. Proc. Natl Acad. Sci. USA 1999, 96:1904-1909.
17. Arai F., Hirao A., Ohmura M., et al. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell 2004, 118:149-161.
18. Moore K.A., Lemischka I.R. "Tie-ing" down the hematopoietic niche. Cell 2004, 118:139-140.
19. Oval J., Jones O.W., Montoya M., et al. Characterization of a factor-dependent acute leukemia cell line with translocation (3;3)(q21;q26). Blood 1990, 76:1369-1374.
20. Oval J., Smedsrud M., Taetle R. Expression and regulation of the EVI-1 gene in the human factor-dependent leukemia cell line, UCSD/AML1. Leukemia 1992, 6:446-451.
21. Hamaguchi H., Suzukawa K., Nagata K., et al. Establishment of a novel human myeloid leukaemia cell line (HNT-34) with t(3;3)(q21;q26), t(9;22)(q34;q11) and the expression of EVI1 gene, P210 and P190 BCR/ABL chimaeric transcripts from a patient with AML after MDS with 3q21q26 syndrome. Br. J. Haematol. 1997, 98:399-407.
22. Asou H., Suzukawa K., Kita K., et al. Establishment of an undifferentiated leukemia cell line (Kasumi-3) with t(3;7)(q27;q22) and activation of the EVI1 gene. Jpn. J. Cancer Res. 1996, 87:269-274.
23. Martin P., Papayannopoulou T. HEL cells: a new human erythroleukemia cell line with spontaneous and induced globin expression. Science 1982, 216:1233-1235.
24. Gallagher R., Collins S., Trujillo J., et al. Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia. Blood 1979, 54:713-733.
25. Sundstrom C., Nilsson K. Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int. J. Cancer 1976, 17:565-577.
26. Lozzio C.B., Lozzio B.B. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 1975, 45:321-334.
27. Matsuo Y., Adachi T., Tsubota T., et al. Establishment and characterization of a novel megakaryoblastic cell line, MOLM-1, from a patient with chronic myelogenous leukemia. Hum. Cell 1991, 4:261-264.
28. Saito Y., Nakahata S., Yamakawa N., et al. CD52 as a molecular target for immunotherapy to treat acute myeloid leukemia with high EVI1 expression. Leukemia 2011, 25:921-931.
29. Gomei Y., Nakamura Y., Yoshihara H., et al. Functional differences between two Tie2 ligands, angiopoietin-1 and -2, in regulation of adult bone marrow hematopoietic stem cells. Exp. Hematol. 2010, 38:82-89.
30. Yu H., Yuan Y., Shen H., et al. Hematopoietic stem cell exhaustion impacted by p18 INK4C and p21 Cip1/Waf1 in opposite manners. Blood 2006, 107:1200-1206.
31. Sirin O., Lukov G.L., Mao R., et al. The orphan nuclear receptor Nurr1 restricts the proliferation of haematopoietic stem cells. Nat. Cell Biol. 2010, 12:1213-1219.
32. Schliemann C., Bieker R., Padro T., et al. Expression of angiopoietins and their receptor Tie2 in the bone marrow of patients with acute myeloid leukemia. Haematologica 2006, 91:1203-1211.